Extract

•To estimate the incidence and severity of adverse reactions in adult patients treated with ipilimumab in the post-approval setting. •To describe the management of adverse reactions (eg, diarrhea, colitis, hepatitis, elevated liver enzymes, hypopituitarism, hypothyroidism, rash, neurologic syndromes) and their outcomes in ipilimumab-treated patients in the post-approval setting

Inclusion criteria

• Patients diagnosed with unresectable or metastatic melanoma, cutaneous, ocular, mucosal and unknown primary tumor

Links

• ictrp
• euctr